Skip to content

Pazopanib

Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: GW 786034, GW786034B, pazopanib HCl, pazopanib hydrochloride, votrient

OfpEMA approvedFDA approvedATC L01EX03

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Pazopanib is an ofp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2009. Its mechanism of action is classified as Cytochrome P450 2C8 Inhibitors, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A4 Inhibitors. DrugCentral lists 112 molecular targets, including CA12, KIT and PDGFRB. Recorded indications include Renal cell carcinoma and Sarcoma of soft tissue.

  • Approval status: ofp (first approved 2009 by the FDA).
  • Drug class: Kinase Inhibitor.
  • Mechanism of action: Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A4 Inhibitors.
  • Molecular targets: CA12, KIT, PDGFRB and PDGFRA (112 listed in DrugCentral).
  • Indications: Renal cell carcinoma and Sarcoma of soft tissue.
  • ATC code: L01EX03 (Other protein kinase inhibitors).
  • Molecular formula: C21H23N7O2S; molecular weight 437.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Renal cell carcinoma
  • Sarcoma of soft tissue

Contraindications (30)

  • Acute hemorrhage
  • Acute Thromboembolic Stroke
  • Angina pectoris
  • Cardiovascular event risk
  • Cerebral hemorrhage
  • Congenital long QT syndrome
  • Diarrhea
  • Drug-induced hepatitis
  • Gastrointestinal fistula
  • Gastrointestinal hemorrhage
  • Gastrointestinal perforation
  • Hepatic failure
  • Hyperbilirubinemia
  • Hypertensive disorder
  • Hypertensive urgency
  • Hypocalcemia
  • Hypokalemia
  • Hypomagnesemia
  • Hypothyroidism
  • Impaired wound healing
  • Liver function tests abnormal
  • Myocardial infarction
  • Pancreatitis
  • Pregnancy, function
  • Prolonged QT interval
  • Proteinuria
  • Surgical procedure
  • Thromboembolic disorder
  • Torsades de pointes
  • UGT1A1*28 polymorphism

Mechanism & targets

Mechanism of action (MoA)Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A4 Inhibitors; Protein Kinase Inhibitors
Established pharmacologic classKinase Inhibitor

Molecular targets (112)

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2010-06-14EMA——
2009-10-19FDA—NOVARTIS PHARMS CORP

ATC classification

ATC codeTherapeutic hierarchy
L01EX03ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label: HLA-B · Informative PGx
  • FDA label: HLA-B, UGT1A1 · Informative PGx
  • HCSC label: HLA-B · Actionable PGx
  • Swissmedic label: HLA-B · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Malignant neoplasm progression2294.6
Hair colour changes1592.9
Death1159.6
Diarrhoea1056.7
Disease progression542.6
Metastases to lung437.5
Decreased appetite425.5
Hypertension394.4
Palmar-plantar erythrodysaesthesia syndrome369.4
Product use in unapproved indication363.8
Fatigue339.7
Nausea315.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Pazopanib is on its molecule page.

Molecular formulaC21H23N7O2S
Molecular weight437.52 g/mol
CAS number444731-52-6
InChIKeyCUIHSIWYWATEQL-UHFFFAOYSA-N
PubChem CID10113978
CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=NC(NC2=CC(=C(C)C=C2)S(N)(=O)=O)=NC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pazopanib used for?

DrugCentral lists the following indications for Pazopanib: Renal cell carcinoma and Sarcoma of soft tissue.

How does Pazopanib work?

Pazopanib is classified as Cytochrome P450 2C8 Inhibitors, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A4 Inhibitors; its molecular targets in DrugCentral include CA12, KIT (inhibitor), PDGFRB (inhibitor) and PDGFRA (inhibitor).

When was Pazopanib first approved?

Pazopanib was first approved by the FDA in 2009.

What drug class does Pazopanib belong to?

Pazopanib is in the Kinase Inhibitor class.

What is the chemical formula of Pazopanib?

Pazopanib has the molecular formula C21H23N7O2S and a molecular weight of 437.52 g/mol.

Browse: all drugs starting with P · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2009-10-19
AgencyFDA
Targets112
Indications2
FormulaC21H23N7O2S
DrugCentral ID4118
Interactive profile